Jubilant Pharmova’s Board of Directors approved the unaudited financial results for Q2 FY26 at its meeting on October 31, 2025. The meeting, which began at 11:40 AM and concluded at 12:50 PM, encompassed the approval of both standalone and consolidated financial results. The company simultaneously posted these documents on its website, with key details available to investors.
Financial Performance Overview
The Board of Directors of Jubilant Pharmova has officially approved the unaudited financial results, including both standalone and consolidated figures, for the quarter and half-year ending September 30, 2025 (Q2 FY26). The decision was made during a board meeting held on October 31, 2025.
Key Financial Figures (Standalone)
Key highlights from the standalone unaudited results include:
- Revenue from operations: ₹663 million for the quarter.
- Total Income: ₹672 million.
- Profit before tax: ₹85 million.
- Net (loss)/profit for the period from continuing operations: ₹(480) million.
Discontinued Operations Impact
The results reflect the impact of discontinued operations, with a Net profit/(loss) after tax of ₹433 million from these operations.
Consolidated Results Highlights
Key highlights from the consolidated unaudited results include:
- Revenue from operations: ₹19,578 million for the quarter.
- Total Income: ₹19,762 million.
- Profit before tax: ₹1,903 million.
- Net profit for the period: ₹1,199 million.
Segment Performance
The consolidated results include a segment-wise breakdown with Radiopharma contributing ₹8,971 million, and Contract Development and Manufacturing Organisation – Sterile Injectables contributing ₹4,115 million to the total revenue.
Business Transfer Impact
The standalone financial results reflect the impact of the business transfer of the Active Pharmaceutical Ingredients (API) business. This change is categorized under discontinued operations. Details can be found at the company’s website.
Source: BSE
